Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as ...

– Pivotal clinical program for lorundrostat as a treatment of patients with uncontrolled and resistant hypertension ongoing, with topline data from Advance-HTN and Launch-HTN trials expected in first ...

CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.

– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

SAN DIEGO, CA—Renal denervation using ultrasound may be more effective than radiofrequency ablation for lowering blood pressure in patients with resistant hypertension, a preliminary head-to-head ...

BOSTON, MA—It’s a surprise turnaround for a trial that once was poised to put the brakes on renal denervation once and for all. Long-term follow-up of hypertension patients treated with the Symplicity ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “In this final follow-up from the SIMPLICITY HTN-3 trial ...

Mineralys Therapeutics, Inc. announced that new long-term efficacy and safety data from the Company's ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...